JBM (Healthcare) Expects at Least 50% Higher H1 Profit

MT Newswires Live11-01

JBM (Healthcare) (HKG:2161) expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, according to a Friday filing with the Hong Kong bourse.

The company attributed the increase in profit to the robust sales momentum of the group's key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segment, supported by the sustained growth of the group's concentrated Chinese medicine granules business.

The company plans to publish its interim results on Nov. 19.

The Medicine company's shares were up about 22% at the close of trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480791270?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-01 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2480791270","market":"sg","top_or_hot":-1,"title":"JBM (Healthcare) Expects at Least 50% Higher H1 Profit","media":"MT Newswires Live","content":"<html><body><p> JBM (Healthcare) (HKG:2161) expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, according to a Friday filing with the Hong Kong bourse.</p><p>The company attributed the increase in profit to the robust sales momentum of the group's key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segment, supported by the sustained growth of the group's concentrated Chinese medicine granules business.</p><p>The company plans to publish its interim results on Nov. 19.</p><p>The Medicine company's shares were up about 22% at the close of trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JBM (Healthcare) Expects at Least 50% Higher H1 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJBM (Healthcare) Expects at Least 50% Higher H1 Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-01 16:46 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>JBM (Healthcare) (HKG:2161) expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2480791270","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480791270","pubTimestamp":1730450818,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"JBM   expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, according to a Friday filing with the Hong Kong bourse.The company attributed the increase in profit to the robust sales momentum of the group's key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segment, supported by the sustained growth of the group's concentrated Chinese medicine granules business.The company plans to publish its interim results on Nov. 19.The Medicine company's shares were up about 22% at the close of trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1606":"中医药概念","BK4137":"综合支持服务","02161":"健倍苗苗","HCSG":"医疗保健服务"},"translate_title":"JBM（医疗保健）预计上半年利润至少增长50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"02161":0.9},"content_text":"JBM (Healthcare) (HKG:2161) expects profit attributable to shareholders to increase at least 50% for the six months ended Sept. 30 compared with the corresponding period of the previous year, according to a Friday filing with the Hong Kong bourse.The company attributed the increase in profit to the robust sales momentum of the group's key brands, notably Ho Chai Kung in the branded medicines segment and Po Chai Pills in the proprietary Chinese medicines segment, supported by the sustained growth of the group's concentrated Chinese medicine granules business.The company plans to publish its interim results on Nov. 19.The Medicine company's shares were up about 22% at the close of trade.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480791270"}